3,4-Dimethoxydalbergione (3,4-DMD) is a natural product isolated from the heartwood of the Brazilian tree, Dalbergia ecastaphyllum. It exhibits a range of biological activities, including antioxidant, anti-inflammatory, and anticancer properties. Research has shown that 3,4-DMD possesses potent cytotoxic effects against various cancer cell lines, particularly those associated with leukemia, breast, and colon cancers. Its mechanism of action involves the induction of apoptosis (programmed cell death) and the inhibition of cell proliferation. 3,4-DMD is also known to suppress the production of pro-inflammatory cytokines, contributing to its anti-inflammatory effects. Due to its promising biological activities, 3,4-DMD has become a subject of intense scientific investigation, with researchers exploring its potential as a therapeutic agent for various diseases. Further research is ongoing to elucidate its detailed pharmacological mechanisms and to evaluate its safety and efficacy in clinical settings.'
3,4-dimethoxydalbergione: substance from Brazilian rosewood substitute which causes dermatitis; RN given refers to (R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 115019 |
| CHEMBL ID | 1591258 |
| CHEBI ID | 185140 |
| SCHEMBL ID | 17131830 |
| MeSH ID | M0086301 |
| Synonym |
|---|
| KBIO1_001152 |
| DIVK1C_006208 |
| SDCCGMLS-0066545.P001 |
| SPECTRUM5_000306 |
| SPECTRUM_000558 , |
| SPECTRUM4_001593 |
| KBIO2_003606 |
| KBIO2_001038 |
| KBIOSS_001038 |
| KBIO2_006174 |
| KBIOGR_002206 |
| SPECPLUS_000112 |
| SPBIO_000268 |
| SPECTRUM2_000304 |
| SPECTRUM240828 |
| NCGC00160161-01 |
| 2,3-dimethoxy-5-(1-phenylprop-2-en-1-yl)cyclohexa-2,5-diene-1,4-dione |
| LMPK12100076 |
| (r)-3,4-dimethoxydalbergione |
| 3755-64-4 |
| CHEBI:185140 |
| 2,3-dimethoxy-5-[(1r)-1-phenylprop-2-enyl]cyclohexa-2,5-diene-1,4-dione |
| CHEMBL1591258 |
| 2,3-dimethoxy-5-((1r)-1-phenyl-2-propenyl)-2,5-cyclohexadiene-1,4-dione |
| 3,4-dimethoxydalbergione |
| 2,5-cyclohexadiene-1,4-dione, 2,3-dimethoxy-5-(1-phenyl-2-propenyl)-, (r)- |
| CCG-38581 |
| 2,3-dimethoxy-5-[(1r)-1-phenylallyl]-1,4-benzoquinone |
| SCHEMBL17131830 |
| sr-05000002540 |
| SR-05000002540-1 |
| (r)-2,3-dimethoxy-5-(1-phenylallyl)cyclohexa-2,5-diene-1,4-dione |
| BRD-K84463716-001-02-5 |
| DTXSID70958625 |
| Class | Description |
|---|---|
| ubiquinones | Any benzoquinone derived from 2,3-dimethoxy-5-methylbenzoquinone; one of a group of naturally occurring homologues. The redox-active quinoid moiety usually carries a polyprenoid side chain at position 6, the number of isoprenoid units in which is species-specific. Ubiquinones are involved in the control of mitochondrial electron transport, and are also potent anti-oxidants. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 22.3342 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 0.8913 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 11.2202 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.9445 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 29.9033 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 3.9811 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 12.9676 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 4 (33.33%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||